Pressmeddelanden från Photocure

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review

Press release – Oslo, Norway, August 4, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharm...

Cision • 04 Aug 14:39

Photocure ASA: Results for the second quarter of 2025

Oslo, Norway, 30 July 2025 - Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 135.

Cision • 30 Jul 07:00

Photocure ASA: Invitation to presentation of second quarter and first half year 2025 financial results

Oslo, Norway, 22 July 2025: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2025 financial results ...

Cision • 22 Jul 08:00

Photocure ASA - Share option grant

Oslo, Norway, 23 June 2025 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Cision • 23 Jun 14:55

Photocure ASA: Results for the first quarter of 2025

Oslo, Norway, 08 May 2025 - Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 125.

Cision • 08 May 07:00

Photocure ASA: Annual general meeting held

Oslo, Norway, 5 May 2025: Photocure ASA (OSE: PHO), held its annual general meeting on 5 May 2025 at 17:00 hours (CEST).

Cision • 05 May 18:11

Photocure ASA: Invitation to presentation of first quarter 2025 financial results

Oslo, Norway, 30 April 2025: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2025 financial results on Thursday 8 May 20...

Cision • 30 Apr 20:57

Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making

Press Release – Oslo, Norway, April 29, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at...

Cision • 29 Apr 08:00

Photocure ASA - Notice of the Annual General Meeting 5 May 2025

Oslo, Norway, 11 April 2025: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 5 May 2025 at 17:...

Cision • 11 Apr 15:28

Photocure ASA: Annual Report 2024

Oslo, Norway, 11 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2024.

Cision • 11 Apr 15:19

Photocure ASA: Transactions made under share buyback program

Oslo, Norway, 2 April 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 ...

Cision • 02 Apr 08:50

Photocure ASA: Transactions made under share buyback program

Oslo, Norway, 31 March 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19...

Cision • 31 Mar 22:48

Photocure ASA - Share option grant to Vice President and General Manager EMEA

Oslo, Norway, 26 March 2025 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to Jane Healy, the Company's newly appointe...

Cision • 26 Mar 08:55

Photocure appoints Jane Healy as Vice President and General Manager EMEA

Press Release – Oslo, Norway, March 26, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane ...

Cision • 26 Mar 08:00

Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

Press Release – Oslo, Norway, March 24, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at ...

Cision • 24 Mar 17:00

Photocure ASA: Initiation of a share buyback

Oslo, Norway, 19 March 2025: Photocure ASA (the "Company") has decided to initiate a buyback of up to 200,000 of its own shares for a total ...

Cision • 19 Mar 18:00

New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence

Press Release – Oslo, Norway, March 14, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study “...

Cision • 14 Mar 08:00

Photocure ASA: Results for the fourth quarter of 2024

Oslo, Norway, 19 February 2025 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 128.

Cision • 19 Feb 08:00

News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared

Press Release – Oslo, Norway, February 17, 2025: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces an update regarding its ong...

Cision • 17 Feb 17:00

Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Press Release – Oslo, Norway, February 17, 2025: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on Februar...

Cision • 17 Feb 07:30

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2024 financial results

Oslo, Norway, 12 February 2025: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2024 financia...

Cision • 12 Feb 14:27

Photocure ASA: Transactions made under share buyback program

Oslo, Norway, 16 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on ...

Cision • 16 Jan 08:46

Photocure ASA: Transactions made under share buyback program

Oslo, Norway, 13 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on ...

Cision • 13 Jan 08:00

Photocure ASA: Transactions made under share buyback program

Oslo, 5 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 Decemb...

Cision • 05 Jan 08:47

Photocure ASA - Share option grant

Oslo, Norway, 23 December - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Cision • 23 Dec 2024 08:02

Photocure ASA: Initiation of a share buyback

Oslo, Norway, 19 December 2024: The Company has decided to initiate a buyback of up to 300,000 of its own shares for a total maximum amount ...

Cision • 19 Dec 2024 08:02

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 3 December 2024: Board member Ghizlane Tagmouti has on 3 December 2024 acquired 4,782 shares at a price per share of NOK 50.

Cision • 03 Dec 2024 15:14

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 3 December 2024: Board member Ghizlane Tagmouti has on 2 December 2024 acquired 20,218 shares at an average price of NOK 50.

Cision • 03 Dec 2024 07:00

Photocure ASA: Results for the third quarter of 2024

Oslo, Norway, 13 November 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 120.

Cision • 13 Nov 2024 08:00

Photocure ASA: Invitation to presentation of third quarter 2024 financial results

Oslo, Norway, 6 November 2024: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2024 financial results on Wednesday 13 No...

Cision • 06 Nov 2024 16:48

Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China

Oslo, Norway, November 5, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SS...

Cision • 05 Nov 2024 10:34

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Press Release – Oslo, Norway, September 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...

Cision • 30 Sep 2024 08:00

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Press Release – Oslo, Norway, September 27, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an ag...

Cision • 27 Sep 2024 08:00

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

Press Release – Oslo, Norway, September 17, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...

Cision • 17 Sep 2024 12:09

Photocure ASA: Results for the second quarter of 2024

Oslo, Norway, 7 August 2024 - Photocure ASA (OSE:PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.

Cision • 07 Aug 2024 08:00

Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results

Oslo, Norway, 31 July 2024: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2024 financial results ...

Cision • 31 Jul 2024 12:00

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Oslo, Norway, July 15, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agre...

Cision • 15 Jul 2024 17:52

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Press Release – Oslo, Norway, June 4, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced acti...

Cision • 04 Jun 2024 08:00

Photocure ASA – Annual general meeting held

Oslo, Norway, 23 May 2024: Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).

Cision • 23 May 2024 19:33

Photocure ASA: Results for the first quarter of 2024

Oslo, Norway, 15 May 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 116.

Cision • 15 May 2024 08:00

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Press Release – Oslo, Norway, May 12, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmac...

Cision • 12 May 2024 10:23

Photocure ASA: Invitation to presentation of first quarter 2024 financial results

Oslo, Norway, 8 May 2024: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2024 financial results on Wednesday 15 May 202...

Cision • 08 May 2024 22:36

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Press Release – Oslo, Norway, May 7, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress...

Cision • 07 May 2024 08:00

Photocure ASA – Notice of the Annual General Meeting 23 May 2024

Oslo, Norway, 30 April 2024: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 23 May 2024 at 17...

Cision • 30 Apr 2024 13:48

Photocure ASA: Annual Report 2023

Oslo, Norway, 30 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.

Cision • 30 Apr 2024 11:52

Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy

Press Release – Oslo, Norway, April 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the Ameri...

Cision • 30 Apr 2024 07:30

Photocure ASA – Share option grant

Oslo, Norway, 25 April 2024 – Photocure ASA (the "Company") (OSE: PHO) refers to its previous stock exchange announcement on 21 December 202...

Cision • 25 Apr 2024 21:53

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Press Release – Oslo, Norway, April 8, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congre...

Cision • 08 Apr 2024 12:32

Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference

OSLO, Norway, April 5, 2024 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Da...

Cision • 05 Apr 2024 07:30

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Press release – Oslo, Norway, March 28, 2024: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Racial Diff...

Cision • 28 Mar 2024 13:13

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Press Release – Oslo, Norway, March 18, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharm...

Cision • 18 Mar 2024 10:05

Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO

Press Release – Oslo, Norway, February 23, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...

Cision • 23 Feb 2024 08:34

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Press Release – Oslo, Norway, February 22, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...

Cision • 22 Feb 2024 08:37

Photocure ASA: Results for the fourth quarter of 2023

Oslo, Norway, 21 February 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 114.

Cision • 21 Feb 2024 08:00

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

Oslo, Norway, 19 February 2024: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2023 financia...

Cision • 19 Feb 2024 09:29

Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024

Oslo, Norway, January 29, 2024: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that its partner Asieris presented Phase III...

Cision • 29 Jan 2024 08:47

Photocure ASA – Share option grant

Oslo, Norway, 20 December 2023 - Photocure ASA (the "Company") (OSE: PHO) cancels up to 1,400,428 options and has subsequently re-issued 399...

Cision • 21 Dec 2023 08:00

SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy

Press release – Oslo, Norway, December 1, 2023: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that new evidence from routi...

Cision • 01 Dec 2023 07:30

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Press Release – Oslo, Norway, November 29, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...

Cision • 29 Nov 2023 10:05

Photocure to present at four investor conferences in November/December 2023

Press Release – Oslo, Norway, November 20, 2023: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four i...

Cision • 20 Nov 2023 17:50

Photocure ASA: Results for the third quarter of 2023

Oslo, Norway, 8 November 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 107.

Cision • 08 Nov 2023 08:00

Photocure ASA: Invitation to presentation of third quarter 2023 financial results

Oslo, Norway, 1 November 2023: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2023 financial results on Wednesday 8 Nov...

Cision • 01 Nov 2023 08:21

Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress

Press Release – Oslo, Norway, October 12, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pha...

Cision • 12 Oct 2023 10:32

Photocure Partner Asieris to present first results for its Hexvix Phase III clinical trial in China at the SIU 2023 Annual Meeting

Press Release – Oslo, Norway, October 7, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Phar...

Cision • 07 Oct 2023 08:00

New Health Economic analysis in France concludes there is insignificant cost difference between White Light and Blue Light Cystoscopy use when applying ccAFU guidelines

Press release – Oslo, Norway, October 6, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of “A cost-consequences ...

Cision • 06 Oct 2023 15:07

Photocure ASA: Change of Board Composition

Oslo, Norway, 28 September 2023: Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.

Cision • 27 Sep 2023 18:05

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Press Release – Oslo, Norway, September 20, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...

Cision • 20 Sep 2023 12:17

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 30 August 2023: Board member Dylan Hallerberg has on 29 August 2023 acquired 150,000 shares at an average price of NOK 43.

Cision • 30 Aug 2023 16:06

Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint

Press Release – Oslo, Norway, August 11, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Phar...

Cision • 11 Aug 2023 11:05

Photocure ASA: Results for the second quarter and first half of 2023

Oslo, Norway, 9 August 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 115.

Cision • 09 Aug 2023 08:00

Photocure ASA: Invitation to presentation of second quarter and first half year 2023 financial results

Oslo, Norway, 3 August 2023: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2023 financial results...

Cision • 03 Aug 2023 08:13

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

Press Release – Oslo, Norway, July 6, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmac...

Cision • 06 Jul 2023 10:39

Photocure ASA – Share option grant

Oslo, Norway, 24 May 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Cision • 24 May 2023 08:31

Photocure ASA: Results for the first quarter of 2023

Oslo, Norway, 10 May 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 105.

Cision • 10 May 2023 08:00

Photocure ASA – Correction: Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET).

Cision • 04 May 2023 13:22

Photocure ASA – Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET).

Cision • 03 May 2023 18:41

Photocure ASA: Invitation to presentation of first quarter 2023 financial results

Oslo, Norway, 3 May 2023: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2023 financial results on Wednesday 10 May 202...

Cision • 03 May 2023 11:38

Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light Cystoscopy

Press Release – Oslo, Norway, May 2, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that results from the Nordic Regi...

Cision • 02 May 2023 17:00

Photocure ASA: Annual Report 2022

Oslo, Norway, 12 April 2023: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2022.

Cision • 12 Apr 2023 16:01

Photocure ASA – Notice of the Annual General Meeting 3 May 2023

Oslo, Norway, 12 April 2023: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 3 May 2023 at 17:...

Cision • 12 Apr 2023 16:01

Photocure ASA – Share option grant

Oslo, Norway, 30 March 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Cision • 30 Mar 2023 10:48

Photocure provides update on Karl Storz’s commitment to maximize the commercial adoption of Saphira™ and decision to discontinue flexible BLC tower production in the U.S.

Oslo, Norway, March 21, 2023 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces Karl Storz’s continued commitment to blue lig...

Cision • 21 Mar 2023 21:57

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Oslo, Norway, March 14, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abs...

Cision • 14 Mar 2023 08:00

Photocure ASA: Results for the fourth quarter of 2022

Oslo, Norway, 23 February 2023 Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.

Cision • 23 Feb 2023 08:00

Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC

Press release – Oslo, Norway, February 20, 2023: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from...

Cision • 20 Feb 2023 07:30

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2022 financial results

Oslo, Norway, 16 February 2023: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2022 financia...

Cision • 16 Feb 2023 13:02

New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

Press release – Oslo, Norway, January 3, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Clinical a...

Cision • 03 Jan 2023 07:30

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

Press release – Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at th...

Cision • 05 Dec 2022 07:30

Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting

Oslo, Norway, November 7, 2022: Photocure ASA., (OSE: PHO), announces that The United States Centers for Medicare & Medicaid Services (CMS) ...

Cision • 07 Nov 2022 07:30

Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China

Press Release – Oslo, Norway, November 4, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pha...

Cision • 04 Nov 2022 10:36

Photocure ASA: Results for the third quarter of 2022

Oslo, Norway, 2 November 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 96.

Cision • 02 Nov 2022 08:00

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Oslo, Norway, 25 October 2022: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2022 financial results on Wednesday 2 Nov...

Cision • 25 Oct 2022 08:44

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

Press release – Oslo, Norway, October 4, 2022: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data and it...

Cision • 04 Oct 2022 07:30

Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

Karl Storz and Photocure to collaborate on commercializing the high-definition system Press Release – Oslo, Norway, September 28, 2022: Pho...

Cision • 28 Sep 2022 07:30

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

Press release – Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder Cancer Company, announces the publication of first results fr...

Cision • 20 Sep 2022 07:30

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Press release – Oslo, Norway, September 15, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris P...

Cision • 15 Sep 2022 09:35

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology

Press release – Oslo, Norway, September 8th, 2022: Photocure ASA, The Bladder Cancer Company, is delighted to continue supporting the global...

Cision • 08 Sep 2022 07:30

Photocure appoints Anders Neijber, MD, PhD as Chief Medical Officer, Global Medical Affairs and Clinical Development

Press Release – Oslo, Norway, September 1, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Dr...

Cision • 01 Sep 2022 07:30

Photocure ASA: Results for the second quarter of 2022

Oslo, Norway, 10 August 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 99.

Cision • 10 Aug 2022 08:00

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative d...

Cision • 09 Aug 2022 09:38